Adverse effects of antiepileptic drugs on bone structure: Epidemiology, mechanisms and therapeutic implications

CNS Drugs

Volumn 15, Issue 8, 2001, Pages 633-642

  Pack, A M ^a   Morrell, M J ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBAMAZEPINE; GABAPENTIN; HORMONE; LAMOTRIGINE; OSTEOCALCIN; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROCOLLAGEN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN D;

BIOCHEMISTRY; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; BONE RADIOGRAPHY; BONE STRUCTURE; CALCIUM ABSORPTION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ENZYME INDUCTION; FRACTURE; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERPARATHYROIDISM; LONG TERM EXPOSURE; MORPHOMETRICS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 0034840412     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115080-00006     Document Type: Review

References (59)

1. Lifetime occupational physical activity and risk of hip fracture in women
2. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group
3. Incidence of five common fractures in an institutionalized epileptic population
4. Fracture risk increased in epilepsy
5. Osteopathien bei antiepileptischer langzeittherapie
6. Osteomalacia with long-term anticonvulsant therapy in epilepsy
7. Disturbance of calcium metabolism by anticonvulsant drugs
8. Altered calcium metabolism in epileptic children on anticonvulsants
9. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy
10. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment
11. Normal ranges for bone loss rates
12. Bone density and antiepileptic drugs: A case controlled study
13. Effect of carbamazepine and valproate on bone mineral density
14. Anticonvulsant drugs and vitamin D metabolism
15. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro
16. Anticonvulsant therapy and vitamin D metabolism: Evidence for different mechanisms for phenytoin and phenobarbital
17. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children
18. Anticonvulsant osteomalacia determined by quantitative analysis of bone changes
19. 2 treatment on bone morphometry and biochemical values in anticonvulsant osteomalacia
20. Anticonvulsant osteomalacia in epileptic outpatients
21. Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy
22. Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial
23. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment
24. Bone status in nonambulant epileptic institutionalized youth
25. Precision of dual photon absorptiometry measurements
26. Effects of anti-convulsant drug therapy on bone mineral density in a pediatric population
27. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs
28. Bone mineral density in AED treated women with epilepsy
29. Bone health in women with epilepsy
30. Bone status after long-term anticonvulsant therapy in epileptic patients: Evaluation using quantitative ultrasound of calcaneus and phalanges
31. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults
32. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone
33. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients
34. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy
35. Biochemical evidence for osteomalacia with carbamazepine therapy
36. Anticonvulsant drugs and bone metabolism
37. Vitamin D
38. Carbamazepine and bone mineral metabolism
39. Low plasma 25-hydroxyvitamin D and serum calcium in institutionalized epileptic subjects: Associated risk factors, consequences and response to treatment with vitamin D
40. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs
41. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants
42. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?
43. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children
44. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy
45. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy
46. Biochemical markers of bone turnover
47. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy
48. Increased bone turnover in epileptic patients treated with carbamazepine
49. Bone histomorphometry, vitamin D metabolites and calcium phosphate metabolism in anticonvulsant treatment with carbamazepine
50. 3 on bone-mineral content in carbamazepine-treated epileptic patients
51. Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy
52. Clinical implications of hepatic microsomal enzyme induction by anti-epileptic drugs
53. 3 in epileptic patients treated with phenobarbitone/phenytoin
54. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia
55. 3 in patients on anticonvulsant therapy
56. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat
57. Serum 25-hydroxy calciferol levels and bone mass in children on chronic anti-epileptic therapy
58. Phenytoin affects osteoblastic secretion form osteoblastic rat osteosarcoma 17/2.8 cells in culture
59. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism